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Dear Editor, 
Recently, the U.S. Food and Drug Administration (FDA) approved the bowel preparation 
NER1006, marketed in the United States as Plenvu (Salix Pharmaceuticals, Bridgewater, NJ).   
Three randomized trials compared NER1006 to oral sulfate 1 (Suprep; Braintree Laboratories, 
Braintree, Mass), PEG-ELS plus ascorbate 2 (Moviprep; Salix Pharmaceuticals, Bridgewater, 
NJ), and sodium picosulfate/anhydrous magnesium citrate 3 (Prepopik; Ferring Pharmaceuticals, 
Parsippany, NJ).  NER1006 is administered in only 1000 mLs of active ingredient. The total 
recommended minimum fluid intake with NER1006 is 2000 mL, making it the lowest total 
volume commercially available preparation in the United States. 1-3  A unique feature of 
NER1006, which the FDA apparently considered clinically insignificant, was an unprecedented 
incidence of hypernatremia.  
Table 1 shows the randomized trials of NER1006 by their company assigned names.  
NER1006 was dosed as evening before dosing, split dosing (one dose in the evening and one in 
the morning), or both doses in the morning (Table 1).  Two trials reported the incidence of 
abnormal serum electrolytes immediately before colonoscopy. Both serum sodium and chloride 
increased after NER1006 (Table 1). One trial (DAYB) did not report electrolyte changes.   In 
NOCT the median increase in serum sodium at Visit 2 was 4.0 mmol/L for NER1006 versus 0.0 
mmol/L for oral sulfate solution.  In NOCT the incidence of serum sodium above the upper limit 
of normal was 9.4 times higher than oral sulfate solution (Table 1).  In MORA an elevated serum 
sodium level with split-dose NER1006 occurred 7.5 times more frequently than with PEG-ELS 
plus ascorbate, and 9.4 times higher with morning only dosing.  Electrolyte abnormalities after 
NER1006 were transient and considered not clinically significant. However, in the 3 trials 
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combined, 14 patients developed clinical dehydration with NER1006, compared with 2 patients 
in the comparator arms (1.4% vs 0.2%).  Vomiting occurred in 51 patients receiving NER1006 
vs 8 patients in the comparator arms (5.0% vs 1.0%).  
Review of 3 trials of oral sulfate solution that include all of the other commonly 
prescribed FDA approved bowel preparations, including MoviPrep, Prepopik and 4 liter PEG-
ELS (NuLYTELY:  Braintree Laboratories, Braintree, Mass), confirms that the NER1006 
incidence of hypernatremia is unprecedented.  Hypernatremia and clinical dehydration appear 
clearly increased with NER1006. Hypernatremia may reflect large amounts of sodium ascorbate 
(48.11 grams in the second dose) and sodium sulfate in NER1006 plus insufficient free water 
intake. The more frequent occurrence of dehydration with NER1006 in the trials indicates this 
effect is clinically important. Outside of trials, where patients are often not as healthy as trial 
volunteers, and in elderly patients with limited thirst response, the dehydration risk should be 
expected to increase. That the electrolyte disturbances in the NER1006 trials reversed by the visit 
after colonoscopy is not reassuring, because adverse events from electrolyte disturbance would 
occur on the day or night of preparation.  
After publication of NOCT, I discussed the incidence of hypernatremia with NER1006 in 
Journal Watch Gastroenterology 7.  Subsequently, the manufacturer engaged me, and 
acknowledged the need to encourage clear liquid intake beyond the prescribed 1 liter of required 
additional clear liquids.  The following was added to the language in the “Important Safety 
Information” regarding Plenvu: “It is important to drink sufficient clear liquids before, during 
and after the use PLENVU.  Be sure to consume additional clear liquids after the first and second 
dose of PLENVU.”  Also, the manufacturer commissioned an evaluation by a nephrologist, who 
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also identified concerns about hypernatremia, and made clinical recommendations (reproduced 
in Table 2 by permission of Salix Pharmaceuticals; Howard Franklin). Thus, the manufacturer 
has taken steps to address the risk of hypernatremia.  Nevertheless, NER1006 continues to be 
marketed (http://www.plenvuhcp.com) as “Plenvu delivered a powerful bowel cleanse, with 33% 
less total fluid.”  Effective preparation for colonoscopy results in average fecal effluent volume 
of 2.5-3 liters 8-9.  NER1006 produces similar volumes of effluent 9, making it seem unwise to 
emphasize a reduced total fluid intake because a reduced intake volume may not compensate for 
fecal losses.  A recommendation to take the active ingredient in NER1006 (1 liter) plus an 
additional 2 liters of water or clear liquid to avoid hypernatremia and dehydration seems 
appropriate. 
In summary, NER1006 is associated with an unprecedented incidence of hypernatremia 
in FDA approved preparations. This effect results from a high sodium load and an inadequate 
prescription for free water intake in the clinical trials. Clinicians prescribing NER1006 should 
understand the potential for hypernatremia and dehydration and encourage at least 2 liters of 
water or clear liquid intake in addition to the 1 liter of active ingredient. Caution should be 
exercised in prescribing NER1006 to at-risk populations. 
Sincerely, 
 
Douglas K Rex, MD 
Indiana University School of Medicine 
Indianapolis, Indiana 
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Table 1. Incidence of hypernatremia and dehydration related outcomes in the randomized trials 
of NER 1006 
 
*Administered as split-dose (evening before and morning of colonoscopy) 
**Both doses administered on the day of colonoscopy 
+
 Both doses administered the evening before colonoscopy 
NS: Not stated 
 
 
 
 
 
 NOCT MORA DAYB 
 
NER100
6* 
Trisulfate
* 
NER100
6* 
NER1006
** 
PEG-ELS 
Ascorbate 
(Moviprep)
* 
NER100
6+ 
SP-MC+ 
Number of patients 262 265 262 269 263 235 241 
Elevated serum 
sodium 
39.3% 4.2% 13.4% 17.5% 0 NS NS 
Elevated serum 
chloride 
20.6% 1.5% 17.2% 21.6% 2.3% NS NS 
Dehydration 6(2.3%) 1(0.4%) 1(0.4%) 4(1.5%) 1(0.4%) 3(1.3%) 0 
Nausea 16(6.1%) 4(1.5%) 12(4.6%) 13(4.8%) 9(3.4%) 6(2.6%) 2(0.8%) 
Vomiting 13(5.0%) 5(1.9%) 10(3.8%) 17(6.3%) 3(1.1%) 11(4.7%) 0 
Treatment 
emergent adverse 
events related to 
study agent 
39(14.9%
) 
25(9.4%) 
30(11.5%
) 
40(14.9%) 20(7.6%) 
28(11.9%
) 
10(4.1%
) 
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Table 2. Summary/Recommendations from the consulting nephrologist (published with 
permission of Salix Pharmaceuticals) 
 
• There is a rise in Na in 39% of patients (average 141-144). This is not clinically 
significant in itself, but patients already at risk could develop hypernatremia with use of 
the bowel prep. 
• The rise in Na most likely results from an approximately equal volume of fecal water 
excretion with decreased water intake, resulting in net dehydration of 1L free water.  
• A rise in Na above 145 is associated with increased mortality in multiple patient 
population study groups and the risk should be taken seriously, although it is not well 
established to what degree this is causative versus associative. 
• Groups at increased risk for hypernatremia include geriatric patients, patients with 
diminished thirst mechanism or poor access to water, patients with impaired mental 
status, patients taking diuretics, chronic kidney disease (particularly with a GFR <60), 
particularly patients with medullary disease (polycystic kidney disease, medullary cystic 
disease, tubular disorders), patients with diabetes insipidus, or patients taking 
medications or with conditions that would cause an osmotic diuresis (ie, mannitol, 
hyperglycemia), pediatric patients, patients with acute kidney injury, or ICU patients.  
• NER1006 is a novel bowel prep with features and benefits (low volume, pleasant taste) 
that are of clinical value. In a number of large, randomized, clinical trials, the product 
was found to be safe and effective. Hypernatremia was identified in a proportion of 
patients taking NER1006 at a higher rate than comparators. As a general precaution I 
would recommend the encouragement of additional free water intake for patients who 
take NER1006, particularly in the patient populations identified above that might be at 
increased risk; this should help to ensure that hypernatremia would probably be avoided. 
 
